Will easily go to $2.50 short term imo bought 110000 shares for a trade. The market is forward looking and GV will rise in anticipation of improved results.
This is gonna get wild
Can you explain clearly what your point is?
What is the relevance to the September 15 date in terms of a possible settlement of any of the lawsuits.
We will find out Monday if they were right, but usually companies don't release bad news pre-market on a Monday.
I have not seen ANY biotech with a very promising treatment with a large market going into Phase 3 trade
under cash value.
MEIP has been basing for so long and has so many catalysts I think it is ripe for a rapid move up.
MEIP is cheapest biotech on NASDAQ
Incredible Phase 2 results for AML Phase 3 later this year
Trades BELOW cash value
SNSS had $500 MM market cap based on Phase 3 AML drug